AngioDynamics Inc Q3 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jayson Bedford - Raymond James Financial, Inc. - Analyst : Good morning. Can you hear me okay?

Question: Jayson Bedford - Raymond James Financial, Inc. - Analyst : I guess Okay, maybe just a few here. So you piqued my interest with your comments around the results of the APEX trial or when do we see data from that trial?

Question: Jayson Bedford - Raymond James Financial, Inc. - Analyst : Okay. And can you just remind us on the timing of of enhancements to AlphaVac?

Question: Jayson Bedford - Raymond James Financial, Inc. - Analyst :

Question: Jayson Bedford - Raymond James Financial, Inc. - Analyst : Okay. And I appreciate the just on There's obviously a lot of moving pieces here. I appreciate that you're not changing guidance outside of the divestiture, but the guidance plus it seems to imply a little slower growth in the fiscal fourth quarter. Are you seeing anything relative to the third quarter specifically? Is there anything that you're seeing specifically in the business? Or is this just more a function of not wanting to make it no easier by keeping the guidance as is. In addition,

Question: Jayson Bedford - Raymond James Financial, Inc. - Analyst : Okay. Maybe just last one for me. You kind of alluded to capital deployment plans. You've got a lot of cash I realize there's a need to fund the business, but any thought of either kind of buyback or just being a little bit more active with the cash?

Question: Jayson Bedford - Raymond James Financial, Inc. - Analyst : Okay. Thank you.

Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst : Thank you. Good morning, Jim and Steve. I guess first, can you talk about the rollout plans for for AlphaVac in PE. what kind of training effort will be needed? Will you look to add to the commercial team, so as not to impact AngioVac, just wondering how you're thinking about that?

Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst : As Jim and Steve, you mentioned on gross margin, he does have some ebbs and flows. And just in terms of an early look at FY '25, I mean, directionally, do you anticipate gross margin on a pro forma basis being up or any any color that you can provide?

Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst : And just lastly, just on cash, you're obviously you're clear in terms of the gross margin impact of the most recently divested products where they have cash accretive, though, just any how should we be thinking about what kind of cash that those businesses through off that may not be in place or are they not Thanks.

Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst : Okay, got it. Thank you, guys.

Question: Jon Young - Canaccord Genuity Group Inc. - Analyst : Good morning, Jim and Steve. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 04, 2024 / 12:00PM, ANGO.OQ - Q3 2024 AngioDynamics Inc Earnings Call Thanks for taking our questions. Maybe just to turn back to the AlphaVac with a new indication and can you talk about what the commercial sales force size is today, how many centers here and just the approach going forward, do you think you need more registries and studies given just the high level of data that's being generated in this sector. And lastly, just on pricing strategy.

Question: Jon Young - Canaccord Genuity Group Inc. - Analyst : Thank you. So transparent about a lot at you. And just turning to now nice to have and the strong quarter you had around there. Can you talk about what's clicking there? When can we see the initial preserve data this year? And is there any way to characterize how much of the probe sales were for prostate? Thanks much, again, taking the question.

Question: Jon Young - Canaccord Genuity Group Inc. - Analyst : Great. Thank you.